Dr. Milan J Anadkat, MD
Claim this profileWashington University School of Medicine
Studies Actinic Keratosis
Studies Keratoderma Blennorrhagicum
6 reported clinical trials
9 drugs studied
Affiliated Hospitals
Clinical Trials Milan J Anadkat, MD is currently running
HT-001
for Skin Side Effects from Cancer Therapy
The goal of this clinical trial is to learn about HT-001 Topical Gel for treatment of EGFR inhibitor-induced skin toxicities. The main questions it aims to answer are: * Determine the therapeutic effect of HT-001 for treatment of patients who develop acneiform rash undergoing Epidermal Growth Factor inhibitor (EGFRI) therapy using the acneiform rash investigator's global assessment scale \[ARIGA\] * Evaluate the safety of HT-001 during treatment Participants will apply HT-001 Gel once per day for 6 weeks, during which the effect on treating acneiform rash or other skin disorders induced by EGFRI therapy will be evaluated using different assessment tools to measure severity of rash, pain, and itching (pruritus), as well as the change in quality of life. The study will be completed in 2 periods: the first period is open-label (unblinded) and all patients will receive HT-001 topical gel with the active ingredient; the second period is blinded and patients will be randomized to receive one of three concentrations of HT-001 or placebo. Researchers will compare HT-001 to the placebo in the second period to see if HT-001 provides a significant treatment effect.
Recruiting0 awards Phase 2
Topical Gel
for Acne-like Skin Issues from Cancer Treatment
This trial tests a special gel applied regularly for a few weeks to help cancer patients with specific skin rashes from their treatment. The gel aims to reduce and soothe these rashes.
Recruiting0 awards Phase 29 criteria
More about Milan J Anadkat, MD
Clinical Trial Related1 year of experience running clinical trials · Led 6 trials as a Principal Investigator · 4 Active Clinical TrialsTreatments Milan J Anadkat, MD has experience with
- HT-001
- HT-001 Placebo
- Calcipotriene
- Fluorouracil
- LUT014 Gel
- Calcipotriol And 5-fluorouracil Cream
Breakdown of trials Milan J Anadkat, MD has run
Actinic Keratosis
Keratoderma Blennorrhagicum
Squamous Cell Carcinoma
Skin Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Milan J Anadkat, MD specialize in?
Milan J Anadkat, MD focuses on Actinic Keratosis and Keratoderma Blennorrhagicum. In particular, much of their work with Actinic Keratosis has involved treating patients, or patients who are undergoing treatment.
Is Milan J Anadkat, MD currently recruiting for clinical trials?
Yes, Milan J Anadkat, MD is currently recruiting for 4 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Milan J Anadkat, MD has studied deeply?
Yes, Milan J Anadkat, MD has studied treatments such as HT-001, HT-001 Placebo, Calcipotriene.
What is the best way to schedule an appointment with Milan J Anadkat, MD?
Apply for one of the trials that Milan J Anadkat, MD is conducting.
What is the office address of Milan J Anadkat, MD?
The office of Milan J Anadkat, MD is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.